Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to delay disease progression.
Treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.
To reduce the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs.
Treatment of major depressive disorder (MDD) in adults.
Long term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.
Maintenance treatment of opioid dependence, as part of a complete treatment plan to include counseling and psychosocial support.
First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 ...
Major depressive disorder.